Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Trends Mol Med. 2019 Sep;25(9):803–816. doi: 10.1016/j.molmed.2019.07.004

Figure 1: Pluripotent stem cell-based therapeutics for muscular dystrophy.

Figure 1:

PSC-derived myogenic progenitors could be used for the potential treatment of MD patients through either autologous or allogeneic cell transplantation. For allogeneic transplantation, iPSCs would be derived from somatic cells of a healthy individual. Upon inducing myogenic differentiation, healthy myogenic progenitors obtained from these iPSCs would be transplanted in the MD patient. In the autologous transplantation setting, iPSCs would be derived from the MD patient’s own cells. These patient-specific iPSCs would be corrected for the genetic defect using genome editing techniques to derive gene corrected iPSCs, which would then be differentiated into transplantable gene corrected myogenic progenitors. These myogenic progenitors would then be used for autologous cell transplantation.